SCHEMBL11889474

SCHEMBL11889474

CC(C)(N)COc1ccc2ccccc2c1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 6/20 0.46
SMN1; SMN2 Q16637 4/20 0.46
NCEH1 Q6PIU2 2/20 0.46
NPC1 O15118 4/20 0.43
GAA P10253 2/20 0.43
ALDH1A1 P00352 1/20 0.43
CYP2A6 P11509 1/20 0.42
RAB9A P51151 3/20 0.41
HPGD P15428 2/20 0.41
TP53 P04637 2/20 0.40
POLB P06746 1/20 0.40
TDP1 Q9NUW8 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
CASP3 P42574 1/20 0.39
SENP8 Q96LD8 1/20 0.39
SENP7 Q9BQF6 1/20 0.39
SENP6 Q9GZR1 1/20 0.39
MAPT P10636 1/20 0.39
AAK1 Q2M2I8 2/20 0.38
KMT2A Q03164 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10587435 0.78 LMNA (0.55) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL11889429 0.76 LMNA (0.51) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL20563011 0.76 LMNA (0.49) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL11889200 0.75 SMN1; SMN2 (0.50) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL11889108 0.75 NPBWR1 (0.41) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL11888990 0.75 KMT2A (0.41) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL12466170 0.74 NCEH1 (0.49) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL19608990 0.74 GAA (0.61) LMNASMN1; SMN2NCEH1NPC1GAA
Hydrochloric Acid SCHEMBL11889093 0.74 HTR1B (0.62) LMNASMN1; SMN2NCEH1NPC1GAA
SCHEMBL16252788 0.73 L3MBTL1 (0.46) LMNASMN1; SMN2NPC1RAB9AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2668160-B1 TRPM8 RECEPTOR ANTAGONISTS DOMPÉ FARMACEUTICI S P A (IT) 2015-08-12 EP disclosed
US-8906946-B2 TRPM8 receptor antagonists DOMPE' S.P.A. (IT) 2014-12-09 US disclosed
US-20140031398-A1 TRPM8 RECEPTOR ANTAGONISTS DOMPÉ FARMACEUTICI S.P.A. (IT) 2014-01-30 US disclosed
EP-2668160-A1 TRPM8 RECEPTOR ANTAGONISTS Dompe' S.p.A. (IT) 2013-12-04 EP disclosed
WO-2012101244-A1 TRPM8 RECEPTOR ANTAGONISTS DOMPE' S.P.A. (IT) 2012-08-02 WO disclosed
EP-2481727-A1 TRPM8 receptor antagonists Dompe S.p.A. (IT) 2012-08-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140031398-A1 TRPM8 RECEPTOR ANTAGONISTS TRPM8, TRPM6, TRPM7 LMNA 3526/4885SMN1; SMN2 979/4885NCEH1 1555/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.